ReviewHeliyon2024
Selenium deficiency in inflammatory bowel disease: A comprehensive meta-analysis.
Review in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Selenium: From Redox Signaling to Interactions with the Gut Microbiome.Biological trace element research · 2026Review
- Selenium: A Key Element in Inflammatory Bowel Disease.Antioxidants (Basel, Switzerland) · 2025Review
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Micronutrient deficiencies, particularly selenium, are common in Inflammatory Bowel Diseases and may influence disease progression and severity. Various studies have investigated blood selenium levels in patients with inflammatory bowel disease, but these studies have shown considerable heterogeneity and are generally limited by small sample sizes. Therefore, this study aims to clarify the selenium status in patients with inflammatory bowel disease compared to controls and to explore the potential of selenium supplementation as a therapeutic option. Method: A comprehensive search of online databases from January 1980 to December 2023 was conducted, focusing on studies related to selenium levels in patients with inflammatory bowel disease. The relationship between blood selenium concentrations in inflammatory bowel disease patients and controls was pooled using a random-effects model. Results: From the 1853 references screened, 20 studies were selected based on the inclusion criteria, involving 1792 inflammatory bowel disease patients (including both Crohn's disease and ulcerative colitis cases) and 1648 controls. The meta-analysis demonstrated that inflammatory bowel disease patients have significantly lower selenium levels compared to the control group. This trend was consistent across subgroups differentiated by study characteristics such as design, geographical location, selenium detection methods, types of samples analyzed, and age categories of participants, with particularly notable deficiencies observed in patients with Crohn's disease. The robustness of these findings was supported by sensitivity analysis, and tests for publication bias indicated no significant skewing of results. Conclusion: The analysis confirms that inflammatory bowel disease patients, especially those with Crohn's disease, have significantly lower levels of selenium compared to controls, suggesting that that selenium supplementation may serve as a valuable adjunct to the therapeutic regimen for managing inflammatory bowel disease, particularly in patients identified with selenium insufficiency.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.